GlassScriptPhysician profile
Michael A Finan
NPI 1508813825
$1,599.19
in general payments reported to CMS, 2019-2025
35 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.50 · 2021: $55.38 · 2022: $31.02 · 2023: $214 · 2024: $127 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252 · Travel and Lodging: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.96 |
| Travel and Lodging | $214.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $231.62 | 2021-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $111.45 | 2020-2025 | Imfinzi, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $107.08 | 2022-2025 | |
| Tersera Therapeutics LLC | $90.00 | 2024-2025 | Zoladex |
| Janssen Biotech, INC. | $81.08 | 2025 | Talvey, Balversa, Erleada |
| Eisai INC. | $72.64 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $70.94 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $70.40 | 2025 | Itovebi, Tecentriq, Phesgo |
| Genmab U.S., INC. | $65.67 | 2025 | Tivdak, Epkinly |
| Taiho Oncology, INC. | $57.68 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.28 | 2025 | Opdivo, Opdualag |
| Stemline Therapeutics INC. | $46.10 | 2025 | Orserdu |
| Beone Medicines USA, INC. | $45.83 | 2025 | Brukinsa |
| Exelixis INC. | $42.33 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $41.67 | 2025 | Besremi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.74 | 2025 | Jemperli, Zejula |
| Celgene Corporation | $30.78 | 2025 | Opdualag |
| Pfizer INC. | $27.90 | 2025 | |
| Tempus Ai, INC | $25.94 | 2025 | Xt Cdx |
| Boston Scientific Corporation | $24.59 | 2021 | |
| Celltrion USA INC. | $23.93 | 2025 | Vegzelma |
| Dilon Technologies, INC. | $22.34 | 2024 | Hemoblast Bellows |
| Myriad Genetic Laboratories, INC. | $21.95 | 2024 | Myrisk |
| Abbvie INC. | $21.59 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.18 | 2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $20.78 | 2025 | |
| Astellas Pharma US INC | $18.97 | 2025 | Vyloy |
| Caris Mpi, INC. | $17.32 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $17.12 | 2025 | Iclusig |
| Legend Biotech USA INC. | $16.79 | 2025 | Carvykti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.68 | 2025 | |
| Medtronic, INC. | $16.28 | 2025 | Osteocool Rf Ablation System |
| Incyte Corporation | $15.46 | 2025 | Jakafi |
| Brainlab, INC. | $14.08 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Finan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.